Inner Cosmos

PUBLIC

Name	Inner Cosmos
Tagline	Fingernail-sized BCI implant for depression via skull micro-stimulations
Headquarters	Portola Valley, United States
Founded	2016
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Brain-Computer Interface (BCI)
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$10,000,000)

Links

PUBLIC

• Website: https://innercosmos.ai/
• LinkedIn: https://www.linkedin.com/company/inner-cosmos

Executive Summary

PUBLIC

Inner Cosmos is developing a minimally invasive brain-computer interface (BCI) implant to treat major depressive disorder, a bet that deserves investor attention for its early clinical validation and a regulatory path that is already underway [Neurotech Center, ~2024-2025]. The company's "Digital Pill" is a fingernail-sized device implanted under the scalp skin, designed to deliver targeted micro-stimulations to specific brain networks without penetrating the brain tissue, a technical approach it claims outperforms existing treatments like transcranial magnetic stimulation (TMS) [Neurotech Center, ~2024-2025]. Founded in 2016, the company has progressed from concept to an FDA-approved human trial, reporting interim patient outcomes that show significant symptom improvement over extended periods [Inner Cosmos, May 2025] [MassDevice, pre-2026].

The founding team is anchored by CEO Meron Gribetz, a serial entrepreneur with a background in augmented reality, and bolstered by significant scientific advisors including Ed Boyden, a pioneer in optogenetics and temporal interference brain stimulation techniques [Dealroom.co, ongoing]. To date, the company has raised a single, disclosed $10 million seed round led by Lool Ventures, with participation from KittyHawk VC and Loup Ventures, capital that is funding its clinical development [Bloomberg, 2022]. The business model is a classic medtech hardware-plus-software play, targeting sales to healthcare providers with a potential future layer of subscription services for real-time brain monitoring [Dealroom.co, ongoing].

Over the next 12 to 18 months, the key milestones to watch are the progression and full results of its FDA Early Feasibility Study, the pursuit of subsequent regulatory clearances, and the company's ability to secure the next round of capital necessary to navigate the long and expensive medical device approval process.

Data Accuracy: YELLOW -- Core company facts and funding are corroborated by multiple sources; clinical claims are sourced primarily from company announcements and niche trade publications.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$10,000,000)

Company Overview

PUBLIC

Inner Cosmos was founded in 2016 by a team of entrepreneurs and neurosurgeons, including CEO Meron Gribetz, to develop a minimally invasive brain-computer interface for psychiatric conditions [Crunchbase]. The company is headquartered in Portola Valley, California, a location that places it within the broader San Francisco Bay Area's life sciences and venture capital ecosystem [Crunchbase].

Key milestones have centered on regulatory progress and early clinical validation. The company secured a $10 million seed round in March 2022, led by Lool Ventures [citybiz, 2022-03-30]. A pivotal step was the subsequent approval of an FDA Investigational Device Exemption, clearing the company to begin its first human trial for depression [Neurotech Center, ~2024-2025]. In May 2025, Inner Cosmos reported interim outcomes from its ongoing Early Feasibility Study, citing symptom improvements in its first two patients [Inner Cosmos, May 2025]. The company announced the completion of that FDA Early Feasibility Study in November 2025 [Inner Cosmos, Nov 2025].

Data Accuracy: YELLOW -- Core facts (founding date, HQ, seed round) are confirmed by multiple sources; regulatory and clinical milestones are reported by the company and vertical press but lack independent corroboration.

Product and Technology

MIXED

The core innovation is a hardware implant designed to treat major depressive disorder through targeted stimulation, a departure from both pharmaceutical and more invasive neuromodulation approaches. The company's "Digital Pill" is described as a fingernail-sized brain-computer interface (BCI) placed under the skin on the skull, delivering precise micro-stimulations to specific brain networks without penetrating the brain tissue [Neurotech Center, ~2024-2025]. This minimally invasive profile is a key technical differentiator, positioning it between non-invasive therapies like transcranial magnetic stimulation (TMS) and fully invasive deep brain stimulation (DBS). The product's intended mechanism, described by CEO Meron Gribetz as building a "cochlear implant for depression," suggests a focus on chronic, long-term modulation of neural circuits associated with mood regulation [Neurotech Center, ~2024-2025].

The system's development is anchored by its regulatory progress, which serves as a de facto public feature set. The company has secured an FDA Investigational Device Exemption to conduct a human trial for depression, the first such approval for a depression BCI in two decades [Neurotech Center, ~2024-2025] [Dealroom.co]. Interim data from this ongoing Early Feasibility Study has been released by the company. In a May 2025 update, Inner Cosmos reported that its first patient achieved a 41% improvement in depressive symptoms from baseline, which it characterized as a 27% gain over that patient's best prior response to TMS [Inner Cosmos, May 2025]. A second patient was reported in November 2025 to have achieved an 83% improvement over a 17-month period [Inner Cosmos, Nov 2025]. The company announced the completion of this FDA Early Feasibility Study in late 2025 [Inner Cosmos, Nov 2025]. While detailed specifications on battery life, stimulation parameters, or the accompanying software dashboard are not publicly available, the product's value proposition is clearly tied to these early clinical signals and its regulatory pathway.

Data Accuracy: YELLOW -- Product claims and clinical outcomes are sourced primarily from the company's own communications and niche industry press. The FDA trial status is reported but not independently verified by regulatory documents.

Market Research

PUBLIC The market for a new, targeted intervention in major depressive disorder is driven by the persistent failure of existing treatments for a significant portion of the patient population, a dynamic that has remained largely unchanged for decades despite rising prevalence.

Third-party sizing for the specific market of brain-computer interface (BCI) implants for psychiatric conditions is not yet established. The most relevant analog is the global market for treatment-resistant depression, which is the condition's most severe and costly segment. A 2022 report from Grand View Research estimated the global treatment-resistant depression market size at $1.3 billion, projecting a compound annual growth rate of 3.5% through 2030 [Grand View Research, 2022]. This figure, however, captures only a subset of the total addressable market for depression therapies, which is vastly larger. The World Health Organization has consistently identified depression as a leading cause of disability worldwide, with hundreds of millions of individuals affected [WHO]. The company's cited research positions its solution as targeting "the world's most common chronic disorder" [Neurotech Center, ~2024-2025].

Key demand drivers extend beyond prevalence. The primary tailwind is the well-documented inadequacy of current standard-of-care options for a large cohort of patients.

• High non-response rates. A substantial percentage of patients do not achieve remission with first-line antidepressants or psychotherapy.
• Procedure limitations. Electroconvulsive therapy (ECT), while effective, carries stigma and cognitive side effects. Transcranial magnetic stimulation (TMS) requires repeated clinic visits over weeks.
• Access and cost barriers. Novel pharmaceutical interventions like ketamine and esketamine are expensive, often require monitoring, and are not universally covered by insurance.

Adjacent and substitute markets include the broader neuromodulation device sector, which includes deep brain stimulation for movement disorders and responsive neurostimulation for epilepsy. These markets demonstrate the commercial viability and regulatory pathways for chronically implanted neurostimulators, though they target different anatomical structures and indications. The regulatory force is the most significant macro factor; the U.S. Food and Drug Administration's Center for Devices and Radiological Health (CDRH) oversees a stringent approval process for Class III medical devices. The company's reported receipt of an Investigational Device Exemption for a depression trial is a critical, early gate in this multi-year pathway [Neurotech Center, ~2024-2025].

Given the absence of a confirmed, direct market sizing for psychiatric BCIs, the following table presents analogous market data from public reports to contextualize the potential opportunity.

Market Segment	Size (Estimate)	Source & Year	Notes
Treatment-Resistant Depression (Global)	$1.3B	Grand View Research, 2022	Projected CAGR 3.5% through 2030. Analogous to target patient cohort.
Neuromodulation Devices (Global)	$6.5B	Fortune Business Insights, 2023	Broader device category including DBS, VNS, SCS.

This framing suggests the initial serviceable obtainable market is the subset of treatment-resistant depression patients who are candidates for invasive procedures, a niche measured in the hundreds of thousands in the U.S. alone. The analyst takeaway is that while the total addressable population is enormous, the near-term commercial opportunity is constrained by clinical trial progress, physician adoption, and reimbursement pathways. Success in the initial indication could unlock expansion into other cognitive and mood disorders, dramatically scaling the addressable market. Data Accuracy: YELLOW -- Market sizing relies on analogous third-party reports; company-specific TAM/SAM not publicly disclosed.

Competitive Landscape

MIXED

Inner Cosmos is positioned as a first-mover in a nascent but highly capital-intensive segment: a minimally invasive, skull-mounted brain-computer interface (BCI) specifically for psychiatric indications, a path that avoids the direct brain penetration of more invasive neural recording systems [Bloomberg, 2022].

If the structured facts include at least one named competitor, render a markdown comparison table with header row "Company | Positioning | Stage / Funding | Notable Differentiator | Source"; put the subject in the first row plus 2-5 named competitors. If there are zero named competitors in the structured facts, OMIT the table entirely and write the competitive analysis as prose only, do NOT render a table whose only non-subject row is a placeholder.

After the table (or the framing sentence if there is no table), write 3-4 substantive paragraphs covering: (1) the segment-by-segment competitive map (incumbents vs. challengers vs. adjacent substitutes), (2) where the subject has a defensible edge today (distribution, data, talent, regulation, capital) AND why that edge is durable or perishable, (3) where the subject is most exposed (a named competitor's specific advantage, a category they cannot enter, a channel they do not own), (4) the most plausible 18-month competitive scenario with one named "winner if X" and one named "loser if Y". Avoid generic statements like "the market is competitive", be specific by name. Label MIXED. End with accuracy score.

Output strictly valid JSON, no fences: { "sectionMarkdown": string }

Opportunity

PUBLIC If Inner Cosmos can successfully commercialize a safe, effective, and minimally invasive brain implant for depression, it would establish a new standard of care in a multi-billion dollar treatment-resistant patient population.

The headline opportunity is to become the category-defining neuromodulation platform for psychiatric disorders, beginning with depression. The company's path to this outcome rests on two pieces of cited evidence: its early FDA regulatory progress and its reported patient outcomes. Inner Cosmos has secured an FDA Investigational Device Exemption for a human trial [Neurotech Center, ~2024-2025], a critical first step that validates the regulatory pathway. More concretely, the company's own published interim data shows Patient 1 achieving a 41% improvement in depressive symptoms from baseline, a 27% gain over their prior best TMS treatment, and Patient 2 showing an 83% improvement over 17 months [Inner Cosmos, May 2025 & Nov 2025]. These early signals, while from a very small cohort, provide a tangible, performance-based wedge into a market dominated by therapies with significant side-effect burdens or limited efficacy.

Growth from a clinical study to a commercial platform requires navigating specific, high-impact scenarios. The following table outlines three plausible scaling paths.

Scenario	What happens	Catalyst	Why it's plausible
Dominant TRD Therapy	The Digital Pill becomes the first-line procedural intervention for treatment-resistant depression (TRD), displacing repetitive TMS and invasive VNS/DBS.	Successful completion of a pivotal FDA trial demonstrating superior efficacy and safety.	The company has already completed an FDA Early Feasibility Study [Inner Cosmos, Nov 2025], a structured precursor to larger trials. Early data positions it as a potential improvement over existing neuromodulation [Inner Cosmos, May 2025].
Platform Expansion into Anxiety	The same implant hardware and stimulation platform is approved for generalized anxiety disorder (GAD), a comorbid condition with a similarly large patient population.	Publication of positive depression trial data showing modulation of shared neural circuits (e.g., the amygdala-prefrontal cortex pathway).	The technology's stated mechanism targets brain networks, not a single diagnosis [Neurotech Center, ~2024-2025]. Platform expansion is a common medtech strategy to amortize R&D and regulatory costs across indications.
Subscription Monitoring Model	Revenue shifts from a one-time device sale to a recurring software-as-a-service model for real-time brain activity monitoring and personalized stimulation tuning.	FDA clearance for a chronic-use, adaptive stimulation algorithm paired with a clinician dashboard.	The company's vision includes "real-time brain monitoring dashboards" as part of its long-term business model [Dealroom.co]. This mirrors the successful SaaS transition seen in other implantable medical devices, like cardiac rhythm management.

Compounding success in this space would likely manifest as a clinical data moat. Each successfully treated patient generates proprietary neural response data, which can be used to refine stimulation algorithms, improve patient selection criteria, and demonstrate real-world effectiveness to payers. This creates a feedback loop where better outcomes drive more physician adoption, which in turn generates more data, further widening the efficacy gap versus new entrants. The company's practice of publishing detailed, patient-level interim outcomes [Inner Cosmos, May 2025] suggests an early focus on building this evidence base, though the flywheel is not yet spinning at commercial scale.

The size of the win can be framed by looking at comparable neuromodulation companies. For instance, LivaNova, a public company with a significant franchise in Vagus Nerve Stimulation (VNS) for TRD, holds a market capitalization of approximately $3 billion [Yahoo Finance, April 2025]. A next-generation, less invasive, and potentially more effective BCI platform that captures a meaningful portion of the TRD market could command a similar or greater valuation. In a platform expansion scenario where the technology addresses multiple neuropsychiatric indications, the opportunity scales with the combined addressable patient populations, which number in the tens of millions globally. This outlines the potential ceiling, not a forecast, but provides a concrete benchmark for what category leadership in this space is worth.

Data Accuracy: YELLOW -- Key opportunity components (regulatory status, early data) are cited from company sources and niche trade publications; market comparables and expansion logic are analyst inferences.

Sources

PUBLIC

1. [Neurotech Center, ~2024-2025] Inner Cosmos Raises $10 Million To Treat Depression With BCI Implant | https://www.neurotechcenter.org/media-pr/forbes-magazine/inner-cosmos-raises-10-million-treat-depression-bci-implant

2. [Dealroom.co, ongoing] Inner Cosmos company information funding investors | https://app.dealroom.co/companies/inner_cosmos

3. [MassDevice, pre-2026] Inner Cosmos shares data for psychiatric BCI tech | https://www.massdevice.com/inner-cosmos-data-psychiatric-bci-tech/

4. [Inner Cosmos, ongoing] Inner Cosmos Home Page | https://innercosmos.ai/

5. [Crunchbase, ongoing] Inner Cosmos Crunchbase Company Profile Funding | https://www.crunchbase.com/organization/inner-cosmos

6. [Bloomberg, 2022] Inner Cosmos Makes Brain-Computer Interface to Rival Elon Musk’s Neuralink | https://www.bloomberg.com/news/articles/2022-03-30/inner-cosmos-makes-bci-to-rival-neuralink-elon-musk

7. [citybiz, 2022-03-30] Inner Cosmos raises $10M seed round led by Lool Ventures | https://citybiz.co/article/inner-cosmos-raises-10m-seed-round-led-by-lool-ventures/

8. [Inner Cosmos, May 2025] Clinical Study Update | Q2 2025 | https://innercosmos.ai/2025/05/13/clinical-study-update-q2-2025/

9. [Inner Cosmos, Nov 2025] Clinical Trial Update | FDA Early Feasibility Study Completion | https://innercosmos.ai/2025/11/26/clinical-trial-update-fda-early-feasibility-study-completion/

10. [Life Science Intelligence, ~2023] Meron Gribetz - Inner Cosmos, Private Partnering Interview at LSI USA '23 | https://www.lifesciencemarketresearch.com/videos/meron-gribetz-inner-cosmos-private-partnering-interview-at-lsi-usa-23

11. [YouTube, 2025] Bullpen KOL Interview | Meron Gribetz | JPM Week 2025 | https://www.youtube.com/watch?v=oQDd_ppiZh0

12. [Grand View Research, 2022] Treatment Resistant Depression Market Size Report, 2022-2030 | https://www.grandviewresearch.com/industry-analysis/treatment-resistant-depression-market

13. [Fortune Business Insights, 2023] Neuromodulation Devices Market Size, Share & Industry Analysis, 2023-2030 | https://www.fortunebusinessinsights.com/neuromodulation-devices-market-102085